Alopecia Areata

It was an absolute pleasure to be able to speak with Dr Brett King (Yale School of Medicine, New Haven, CT, USA) about the recent efficacy and safety results presented around the JAK inhibitors, baricitinib and ritlecitinib, in the treatment of alopecia areata.  His presentations entitled 'Efficacy and Safety of Ritlecitinib (PF-06651600) in Patients with Alopecia Areata and ≥50% Scalp Hair Loss: Results from the International ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Study' and 'Efficacy and safety of baricitinib in adults with alopecia areata: Phase 3 results from two randomized controlled trials (BRAVE-AA1 and BRAVE-AA2)' were given at the EADV 30th Congress, 29 Sep - 2 Oct. Questions Could you tell us a little about the ALLEGRO and BRAVE clinical trials, their design and patient populations? (0:14) What were the efficacy and safety findings from these studies and how do they compare? (1:47) With two JAK inhibitors appearing promising in this indication, what are their relative strengths and limitations? (3:47) Disclosures: Dr. Brett King has served on advisory boards and/or is a consultant and/or is a clinical trial investigator for Abbvie, Aclaris Therapeutics Inc, AltruBio Inc, Almirall, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Myers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio. He is on speaker bureaus for Pfizer Inc, Regeneron and Sanofi Genzyme Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival. Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

touchIMMUNOLOGY caught up with William (Bill) Damsky (Yale School of Medicine, New Haven, CT, USA) to discuss hot topics and current educational needs in the treatment of alopecia areata. Disclosures: William Damsky is a consultant for Eli Lilly, Pfizer, and TWi Biotechnology; has received research funding from Pfizer and receives licensing fees from EMD, Millipore […]

touchIMMUNOLOGY caught up with William (Bill) Damsky (Yale School of Medicine, New Haven, CT, USA) to discuss the results from the BRAVE AA1 study (NCT03570749) investigating the use of baricitinib in the treatment of alopecia areata. Questions What is the rationale for the use of JAK inhibitors in the treatment of alopecia areata? (0:12) Could […]

Alopecia areata (AA) is a common dermatological disorder characterized by hair loss of the scalp and/or body, which is often resistant to treatment. It has a substantial impact on body image and self-esteem, resulting in greatly reduced quality of life.1 Its pathogenesis has not been fully elucidated, although increasing evidence suggests that it is a […]